Twinrix Paediatric

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

hepatitis A virus (inactivated), hepatitis B surface antigen

Available from:

GlaxoSmithKline Biologicals S.A.

ATC code:

J07BC20

INN (International Name):

hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)

Therapeutic group:

cjepiva

Therapeutic area:

Immunization; Hepatitis B; Hepatitis A

Therapeutic indications:

Twinrix pedijatrijskih je indiciran za uporabu u sobe imunološki dojenčadi, djece i adolescenata od jedne godine do i uključujući 15 godina koji su u opasnosti od oba hepatitisa A i hepatitisa B infekcije.

Product summary:

Revision: 23

Authorization status:

odobren

Authorization date:

1997-02-10

Patient Information leaflet

                                19
B. UPUTA O LIJEKU
20
UPUTA O LIJEKU: INFORMACIJA ZA KORISNIKA
_ _
_ _
TWINRIX PAEDIATRIC, SUSPENZIJA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
Cjepivo protiv hepatitisa A (inaktiviranog) i hepatitisa B (rDNA)
(HAB) (adsorbirano)
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO VI/ VAŠE DIJETE
POČNETE PRIMATI OVO CJEPIVO JER SADRŽI
VAMA VAŽNE PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se svom liječniku ili
ljekarniku.
-
Ovo cjepivo je propisano samo Vama/Vašem djetetu. Nemojte ga davati
drugima.
_ _
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
_ _
_ _
Ova uputa je pisana s pretpostavkom da će ju čitati osoba koja prima
cjepivo, no cjepivo može biti
dano adolescentu ili djetetu tako da ga Vi možete čitati za svoje
djete.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Twinrix Paediatric i za što se koristi
2.
Što morate znati prije nego primite cjepivo Twinrix Paediatric
3.
Kako se primjenjuje Twinrix Paediatric
4.
Moguće nuspojave
5.
Kako čuvati Twinrix Paediatric
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE TWINRIX PAEDIATRIC I ZA ŠTO SE KORISTI
Twinrix Paediatric je cjepivo namijenjeno za primjenu u djece i
adolescenata od navršene 1. godine
života do uključivo 15. godine, u svrhu prevencije dviju bolesti:
hepatitisa A i hepatitisa B.
Cjepivo djeluje tako da potiče tijelo na stvaranje vlastite zaštite
(protutijela) protiv ovih bolesti.
•
HEPATITIS A:
Hepatitis A je zarazna bolest koja pogađa jetru. Ova je bolest
izazvana virusom
hepatitisa A. Virus Hepatitisa A može se prenijeti s osobe na osobu
hranom ili pićem, ili
plivajući u vodi koja je kontaminirana otpadnim vodama. Simptomi
hepatitisa A počinju 3 do 6
tjedana nakon dolaska u kontakt s virusom. Simptomi uključuju
mučninu, vrućicu i bolove.
Nakon par dana, bjeloočnice i koža mogu požutjeti (žutica).
Težina i tip simptoma
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
_ _
_ _
2
1.
NAZIV LIJEKA
Twinrix Paediatric, suspenzija za injekciju u napunjenoj štrcaljki
Cjepivo protiv hepatitisa A (inaktiviranog) i hepatitisa B (rDNA)
(HAB) (adsorbirano).
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
1 doza (0,5 ml) sadrži:
inaktivirani virus hepatitisa A
1,2
360 ELISA jedinica
površinski antigen virusa hepatitisa B
3,4
10 mikrograma
1
proizveden na humanim
diploidnim (MRC-5) stanicama
2
adsorbiran na aluminijev hidroksid, hidratizirani
0,025 miligrama Al
3+
3
proizveden tehnologijom rekombinantne DNK na stanicama kvasca (
_Saccharomyces cerevisiae_
)
4
adsorbiran na aluminijev fosfat
0,2 miligrama Al
3+
Cjepivo može sadržavati tragove neomicina, koji se koristi tijekom
proizvodnog postupka (vidjeti
dio 4.3).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Suspenzija za injekciju.
Mutno bijela suspenzija.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Twinrix Paediatric indiciran je za primjenu u neimune djece i
adolescenata od navršene 1. godine do
uključivo 15. godina života koji su pod rizikom od zaraze i
hepatitisom A i hepatitisom B.
4.2
DOZIRANJE I NAČIN PRIMJENE
Doziranje
- Doza
Doza od 0,5 ml (360 ELISA jedinica HA/10 µg HbsAg) preporučuje se za
djecu i adolescente od
navršene 1. godine do uključivo 15. godina života.
- Shema primarnog cijepljenja
_ _
Standardno primarno cijepljenje cjepivom Twinrix Paediatric sastoji se
od tri doze, od kojih se prva
primjenjuje odabranog datuma, druga mjesec dana kasnije, a treća
šest mjeseci nakon prve doze. Treba
se pridržavati preporučenog rasporeda. Jednom započeto, primarno
cijepljenje treba dovršiti istim
cjepivom.
3
- Docjepljivanje
U slučaju kada je potrebno docjepljivanje protiv hepatitisa A i/ili
hepatitisa B, može se dati
monovalentno ili kombinirano cjepivo. Nije procijenjena sigurnost i
imunogenost cjepiva Twinrix
Paediatric primijenjenog docjepljivanjem nakon primarnog ciklusa
cijepljenja trima dozama.
Postoje dugoročni podaci o perzistenciji protu
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-02-2024
Public Assessment Report Public Assessment Report Bulgarian 15-04-2008
Patient Information leaflet Patient Information leaflet Spanish 07-02-2024
Public Assessment Report Public Assessment Report Spanish 15-04-2008
Patient Information leaflet Patient Information leaflet Czech 07-02-2024
Public Assessment Report Public Assessment Report Czech 15-04-2008
Patient Information leaflet Patient Information leaflet Danish 07-02-2024
Public Assessment Report Public Assessment Report Danish 15-04-2008
Patient Information leaflet Patient Information leaflet German 07-02-2024
Public Assessment Report Public Assessment Report German 15-04-2008
Patient Information leaflet Patient Information leaflet Estonian 07-02-2024
Public Assessment Report Public Assessment Report Estonian 15-04-2008
Patient Information leaflet Patient Information leaflet Greek 07-02-2024
Public Assessment Report Public Assessment Report Greek 15-04-2008
Patient Information leaflet Patient Information leaflet English 07-02-2024
Public Assessment Report Public Assessment Report English 15-04-2008
Patient Information leaflet Patient Information leaflet French 07-02-2024
Public Assessment Report Public Assessment Report French 15-04-2008
Patient Information leaflet Patient Information leaflet Italian 07-02-2024
Public Assessment Report Public Assessment Report Italian 15-04-2008
Patient Information leaflet Patient Information leaflet Latvian 07-02-2024
Public Assessment Report Public Assessment Report Latvian 15-04-2008
Patient Information leaflet Patient Information leaflet Lithuanian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-02-2024
Public Assessment Report Public Assessment Report Lithuanian 15-04-2008
Patient Information leaflet Patient Information leaflet Hungarian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 07-02-2024
Public Assessment Report Public Assessment Report Hungarian 15-04-2008
Patient Information leaflet Patient Information leaflet Maltese 07-02-2024
Public Assessment Report Public Assessment Report Maltese 15-04-2008
Patient Information leaflet Patient Information leaflet Dutch 07-02-2024
Public Assessment Report Public Assessment Report Dutch 15-04-2008
Patient Information leaflet Patient Information leaflet Polish 07-02-2024
Public Assessment Report Public Assessment Report Polish 15-04-2008
Patient Information leaflet Patient Information leaflet Portuguese 07-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 07-02-2024
Public Assessment Report Public Assessment Report Portuguese 15-04-2008
Patient Information leaflet Patient Information leaflet Romanian 07-02-2024
Public Assessment Report Public Assessment Report Romanian 15-04-2008
Patient Information leaflet Patient Information leaflet Slovak 07-02-2024
Public Assessment Report Public Assessment Report Slovak 15-04-2008
Patient Information leaflet Patient Information leaflet Slovenian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 07-02-2024
Public Assessment Report Public Assessment Report Slovenian 15-04-2008
Patient Information leaflet Patient Information leaflet Finnish 07-02-2024
Public Assessment Report Public Assessment Report Finnish 15-04-2008
Patient Information leaflet Patient Information leaflet Swedish 07-02-2024
Public Assessment Report Public Assessment Report Swedish 15-04-2008
Patient Information leaflet Patient Information leaflet Norwegian 07-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 07-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 07-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 07-02-2024